David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
Betere overleving pPCL met VRd of daratumumab-gebaseerde quadrupeltherapie
apr 2023 | Leukemie, MM